Medical Necessity of Subcutaneous Immunoglobulin for CIDP

Patient Clinical Profile and Indication Assessment

A 29-year-old male with confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Sjogren's disease, previously stable on monthly IVIG, developed allergic reactions and anaphylactic shock, leading to discontinuation of IVIG therapy, and now demonstrates significant clinical deterioration, including reduced activity tolerance requiring assistance with stairs 1
The patient's diagnosis was confirmed by electrodiagnostic studies showing severe sensorimotor demyelinating neuropathy 1
The patient has failed treatments with Gamunex (IVIG), Vyvgart, and intermittent Prednisone 1

The requested dose of Hizentra 2gram/10ml (20%) subcutaneous injection 80ml (16g total) weekly is technically off-label, but the standard SCIg maintenance dosing for CIDP is 200-400mg/kg/week, which translates to approximately 14-28g per week for a typical adult, and the requested 16g weekly dose falls within this therapeutic range 1
Weekly administration is appropriate for maintaining steady immunoglobulin levels 1

Subcutaneous immunoglobulin (SCIg) has been successfully used in patients who experienced anaphylaxis with IVIG, and may be better tolerated for patients with IgA deficiency who developed anti-IgA antibodies 1

The patient meets diagnostic criteria for CIDP with a progressive/relapsing course, moderate to severe functional disability, and confirmation by electrodiagnostic studies 1
The patient was stable on IVIG for 3 years, but experienced anaphylactic shock, and shows significant functional decline since stopping immunoglobulin therapy 1

Regular assessment of clinical response using standardized measures, such as muscle strength and disability scores, is recommended 1
Periodic IgG trough levels should be monitored to ensure adequate replacement 1
Laboratory monitoring, including blood counts and serum chemistry, should be performed at least every 6-12 months 1